FDA guidance steers COVID-19 drug developers to controlled, sub-grouped trials

A pair of new FDA guidance documents covering COVID-19 drug development provides much needed clarity for the hundreds of drugmakers that have embarked on clinical and preclinical development programs for the novel coronavirus over the past four months.

At least 240 clinical and 180 preclinical compounds are in development for the indication, according to BioCentury’s COVID-19 Resource Center...